Are Weight-Loss Drugs Like Gym Memberships? The Answer Is Worth Billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
An Ozempic Expert Explains What You Need to Know Before Taking GLP-1 Drugs
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest Approval
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...
S&P 500 rises, Nasdaq jumps 2% in recovery rally after Nvidia-led sell-off: Live updates
The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...
Outsourcing-pharma22h
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Hosted on MSN22h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...